-
22nd Century Appoints Interim CEO, Implements $15M Cost Reduction Initiative
Monday, July 24, 2023 - 10:26am | 552Read More...22nd Century Group, Inc. (NASDAQ: XXII) announced that John Miller, who leads the tobacco business unit, has been appointed as interim CEO. James A. Mish, who has served as CEO since June 2020, will continue to serve as a member of the board of directors. The company has secured an additional $11.7...
-
22nd Century To Secure $3M Via Registered Direct Offering Priced Above Market
Friday, July 7, 2023 - 10:47am | 441Read More...22nd Century Group, Inc. (NASDAQ: XXII) has entered into definitive agreements with certain investors for the purchase and sale of 778,634 shares of common stock and warrants at a price of $3.80 per share in a registered direct offering priced above market. Gross proceeds to the company from the...
-
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
Friday, September 10, 2021 - 10:21am | 495Read More...Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr. Reddy's Laboratories Ltd (NYSE: RDY) to acquire its exclusive license of E7777, a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare form of non-Hodgkin...
-
Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says
Tuesday, May 26, 2020 - 1:01pm | 352Read More...Sorrento Therapeutics Inc's (NASDAQ: SRNE) coronavirus program has been met with equal optimism and skepticism, which has led to wild swings in its stock price. The Sorrento Analyst Dawson James Securities analyst Jason Kolbert initiated coverage of Sorrento with a Buy rating and a $24...
-
Spring Bank Pharma Sells Off After IPO Pricing
Friday, May 6, 2016 - 3:26pm | 217Read More...Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH), a micro-cap, clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of viral infections, opened at $11.28 on Friday, 6 percent below the IPO price, which was set at $12.00 per share. Trading is scheduled to...
-
UPDATE: Dawson James Securities Initiates Coverage on Vringo on Revved-Up (I/P) Engine
Thursday, November 7, 2013 - 12:33pm | 231Read More...In a report published Thursday, Dawson James Securities analyst Robert M. Wasserman initiated coverage on Vringo (NASDAQ: VRNG) with a Buy rating and $5.25 price target. In the report, Dawson James Securities noted, “Vringo has accomplished a significant amount since completing its merger with IP...
-
UPDATE: Dawson James Securities Raises PT on VirtualScopics Following 2013 Annual Meeting
Tuesday, September 3, 2013 - 8:45am | 152Read More...In a report published Monday, Dawson James Securities analyst Robert M. Wasserman reiterated a Buy rating on VirtualScopics (NASDAQ: VSCP), and raised the price target from $1.75 to $8.75. In the report, Dawson James Securities noted, “VirtualScopics held their 2013 Annual Meeting and reported...
-
UPDATE: Dawson James Securities Initiates Coverage on Onyx Pharmaceuticals with Market Outperform Rating, $91 PT
Friday, December 7, 2012 - 11:49am | 156Read More...In a report published Friday, Dawson James Securities initiated coverage on Onyx Pharmaceuticals (NASDAQ: ONXX) with a Market Outperform rating and $91.00 price target. Dawson James noted, “We are initiating coverage of Onyx Pharmaceuticals with a Market Outperform Rating and a $91 price target....
-
Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals
Wednesday, November 28, 2012 - 10:54am | 85Read More...In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX). Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price...
-
UPDATE: Dawson James Securities Downgrades SeraCare Life Sciences to Neutral
Monday, March 5, 2012 - 11:42am | 143Read More...Dawson James Securities lowers its rate to Neutral on SeraCare Life Sciences (NASDAQ: SRLS) on the buyout of the company by a private equity firm. Dawson James Securities notes, "SeraCare has signed a definitive agreement to be acquired for $4.00 per share in cash by private equity firm Linden...
-
Dawson James Securities: NeuroMetrix Launches New Product
Monday, February 27, 2012 - 11:58am | 178Read More...According to a research report published today by Dawson James Securities, NeuroMetrix Inc. (NASDAQ: NURO) has launched its new product, the NC-stat DPNCheck, for diagnosing diabetic peripheral neuropathy. Dawson James Securities explained further in the report, “[It] has already made inroads in...
-
Dawson James Securities: Level 3 Movin' On Up as Losses Narrow
Monday, February 27, 2012 - 11:55am | 159Read More...In a research report published today by Dawson James Securities, Level 3 Communications Inc. (NYSE: LVLT) reported sales of $1.579 billion for Q4/11, an increase of 71.4% from sales of $921 million in Q4/10. Dawson James Securities commented in the report, “The bulk of revenue growth can be...
-
Dawson James Securities: Ultra Petroleum Reported Mixed 4Q11 Results
Monday, February 27, 2012 - 11:52am | 155Read More...In a research report published earlier today by Dawson James Securities, Ultra Petroleum (NYSE: UPL) recent reported its fiscal 4Q in mid-February, offering mixed results. Dawson James Securities commented in the report, “Ultra reported operating income of $86.3 million in Q4/11, on margins of 31....
